• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session

    6/17/24 7:41:58 AM ET
    $ABSI
    $ABVX
    $AMCX
    $EVO
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABSI alert in real time by email

    U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday.

    Shares of AMC Networks Inc. (NASDAQ:AMCX) fell sharply in today's pre-market trading after the company announced a private offering of $125 million of convertible senior notes.

    AMC Networks shares dipped 9.4% to $14.24 in pre-market trading.

    Here are some big stocks recording losses in today's pre-market trading session.

    • Evotec SE (NYSE:EVO) shares fell 7.7% to $4.20 in pre-market trading.
    • Absci Corporation (NASDAQ:ABSI) declined 5.8% to $3.75 in pre-market trading after declining around 9% on Friday.
    • Humacyte, Inc. (NASDAQ:HUMA) fell 5.7% to $6.65 in pre-market trading.
    • Absci Corporation (NYSE:GCI) fell 5.5% to $4.16 in pre-market trading.
    • ABIVAX Société Anonyme (NASDAQ:ABVX) declined 5.2% to $12.88 in pre-market trading.
    • Infinera Corp (NASDAQ:INFN) shares fell 4.4% to $5.00 in pre-market trading.
    • Larimar Therapeutics, Inc. (NASDAQ:LRMR) shares fell 4% to $9.02 in pre-market trading.
    • Louisiana-Pacific Corporation (NYSE:LPX) shares fell 3% to $89.35 in pre-market trading. Goldman Sachs analyst Susan Maklari downgraded Louisiana-Pacific from Neutral to Sell and lowered the price target from $89 to $81.

    Now Read This: Lennar, La-Z-Boy And 3 Stocks To Watch Heading Into Monday

    Don't forget to check out our premarket coverage here

    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI
    $ABVX
    $AMCX
    $EVO

    CompanyDatePrice TargetRatingAnalyst
    Abivax SA
    $ABVX
    3/16/2026$160.00Buy
    Jefferies
    Abivax SA
    $ABVX
    2/24/2026$110.00Outperform
    Wedbush
    Louisiana-Pacific Corporation
    $LPX
    2/5/2026$15.00Outperform
    Oppenheimer
    Evotec SE
    $EVO
    2/3/2026Buy
    Berenberg
    Absci Corporation
    $ABSI
    1/8/2026$4.32Overweight → Equal-Weight
    Morgan Stanley
    AMC Networks Inc.
    $AMCX
    12/15/2025Buy → Neutral
    Seaport Research Partners
    Louisiana-Pacific Corporation
    $LPX
    12/8/2025$100.00Overweight
    Barclays
    Abivax SA
    $ABVX
    11/24/2025Buy
    Truist
    More analyst ratings

    $ABSI
    $ABVX
    $AMCX
    $EVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Abivax SA with a new price target

    Jefferies initiated coverage of Abivax SA with a rating of Buy and set a new price target of $160.00

    3/16/26 8:36:55 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Abivax SA with a new price target

    Wedbush initiated coverage of Abivax SA with a rating of Outperform and set a new price target of $110.00

    2/24/26 7:44:56 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Louisiana-Pacific with a new price target

    Oppenheimer initiated coverage of Louisiana-Pacific with a rating of Outperform and set a new price target of $15.00

    2/5/26 6:59:51 AM ET
    $LPX
    Forest Products
    Basic Materials

    $ABSI
    $ABVX
    $AMCX
    $EVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Legal Officer Walker Shelby J. was granted 90,300 shares and covered exercise/tax liability with 9,825 shares, increasing direct ownership by 136% to 139,775 units (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    3/16/26 6:56:32 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: CFO / CBO Jonasson Zachariah was granted 135,400 shares and covered exercise/tax liability with 10,848 shares, increasing direct ownership by 33% to 499,783 units (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    3/16/26 6:55:34 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SVP, CAO Bedrick Todd was granted 49,600 shares and covered exercise/tax liability with 5,282 shares, increasing direct ownership by 26% to 216,942 units (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    3/16/26 6:53:54 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    $ABVX
    $AMCX
    $EVO
    SEC Filings

    View All

    AMC Networks Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AMC Networks Inc. (0001514991) (Filer)

    4/3/26 2:00:21 PM ET
    $AMCX
    Cable & Other Pay Television Services
    Telecommunications

    SEC Form 10-K filed by Humacyte Inc.

    10-K - Humacyte, Inc. (0001818382) (Filer)

    3/27/26 4:45:33 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Absci Corporation

    SCHEDULE 13D/A - Absci Corp (0001672688) (Subject)

    3/26/26 5:00:06 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    $ABVX
    $AMCX
    $EVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

    Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"),  a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the fili

    4/1/26 4:05:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

    - Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -  - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Submitted of a Marketing Authorization Application with the Israel Ministry of Health - - U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim result from V012 Phase 3 study in hemodialysis access - - Conference call today at 8:00 am ET - DURHAM, N.C., March 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a c

    3/27/26 7:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

    - Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company's leadership team to expan

    3/26/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABSI
    $ABVX
    $AMCX
    $EVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Busch Andreas bought $229,000 worth of shares (100,000 units at $2.29), increasing direct ownership by 31% to 421,446 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/16/26 4:17:22 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Pangalos Menelas N bought $205,760 worth of shares (75,095 units at $2.74), increasing direct ownership by 66% to 189,055 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/3/26 4:13:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    * Director by Deputization Flynn James E bought $25,000,000 worth of shares (5,000,000 units at $5.00) (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 7:46:04 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ABVX
    $AMCX
    $EVO
    Leadership Updates

    Live Leadership Updates

    View All

    Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

    - Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company's leadership team to expan

    3/26/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat

    3/3/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    LP Building Solutions Names Kaycee Casteel as Vice President, Human Resources

    LP Building Solutions (LP), a leading manufacturer of high-performance building products, today announced the appointment of Kaycee Casteel as Vice President of Human Resources, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105412565/en/ In her new role, Casteel will oversee all HR functions, including workforce strategy, compliance with labor laws and company policies, and talent management across recruitment, retention and succession planning. The promotion consolidates HR leadership under a single executive, aligning with LP's companywide integration strategy introduced in 2025. "Kaycee has consis

    1/5/26 11:00:00 AM ET
    $LPX
    Forest Products
    Basic Materials

    $ABSI
    $ABVX
    $AMCX
    $EVO
    Financials

    Live finance-specific insights

    View All

    Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

    Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported

    3/24/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

    DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 Fourth Quarter and Year End Financial Results and Corporate UpdateDateMarch 27, 2026Time8:00 a.m. Eastern TimeConference Details1-877-704-4453 (U.S. Investors)1-201-389-0920 (International Investors)1

    3/23/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

    VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors

    2/24/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    $ABVX
    $AMCX
    $EVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/20/24 7:10:08 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/18/24 4:10:14 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

    SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

    11/14/24 5:05:19 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care